ESCRS 2023: The three things that make this meeting a priority for Dr Sheng Lim

News
Video

The glaucoma specialist spoke about his ESCRS agenda–and his calendar for 2024

The annual European Society of Cataract and Refractive Surgeons (ESCRS) meeting is considered one of the most important events in ophthalmology. Our team spoke with Sheng Lim, MD, about glaucoma data he presented at the congress, what’s ahead in minimally invasive glaucoma surgery (MIGS) and why he makes the ESCRS meeting a priority each year.

Editor’s note: This transcript has been lightly edited for clarity.

Sheng Lim: My name is Sheng Lim, Professor of Glaucoma Studies at St. Thomas Hospital in King's College, London.

ESCRS is an important meeting for me. I'm always involved in the running of surgical courses, always present some data from my lab, always 1 or 2 papers, here, and presentations. It's also a very important meeting for the industry as well, because all the industries are here. So [it’s] become an important meeting for my calendar every year. So, 3 things: running courses, scientific presentations and meeting [the] industry.

[At ESCRS,] I'm going to have some new data that hasn't been published yet. I think it'll be quite interesting for people who are interested in MIGS devices. You'll be surprised to see some of these newer devices, how they work and how well they work. In a lot of them, these are the first studies that have been done in those devices.

I'm the chief investigator of a first randomised control trial on the [endoscopic cyclophotocoagulation] ECP laser in glaucoma. The data will be out, hopefully, in 2024. For me personally, that is the most exciting thing in my calendar. But, beyond that, there are 2 or 3 new glaucoma devices and surgical techniques that have only just been introduced, and I haven't tried those yet. So I'm looking forward to laying my hands on those, trying it out, and see how well it works. So [it's] quite exciting, here. I look forward to it.


Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.